Research guide
TB-500
TB-500 is a synthetic pentapeptide fragment corresponding to amino acids 17-23 of the full 43-amino-acid thymosin beta-4 protein. It is sold exclusively as a "research chemical" with "not for human consumption" labeling. TB-500 is NOT FDA-approved for any indication and has no recognized medical use by any global regulatory authority. Important distinction: most published thymosin beta-4 research involves the full-length protein, not the TB-500 fragment. TB-500 exists in a regulatory gray zone and is restricted for "research use only" with no human clinical efficacy or safety database.
What the research shows
In preclinical wound healing models, TB-500 showed 42% improved healing status vs. saline controls by day 4; by day 7, wound healing was 61% better in TB-500 groups than saline-treated controls
positive · TB-500 Medical Evidence Review (September 2024) ↗
A Phase IIb clinical trial of recombinant human thymosin beta-4 for acute myocardial infarction was completed in 2023, showing continued clinical interest in thymosin beta-4 for cardiac applications, though full-length protein, not TB-500 fragment
positive · ClinicalTrials.gov (NCT05984134) ↗
TB-500 mechanisms: cell migration acceleration, angiogenesis (new blood vessel formation), inflammation reduction, and tissue remodeling; promotes fibroblast and endothelial cell proliferation in animal models
positive · TB-500 (Thymosin Beta-4) Review 2025: Tissue Repair & Regenerative Potential ↗
A 2019 study noted thymosin beta-4 enhanced muscle cell proliferation, potentially reducing recovery downtime, but TB-500 does NOT appear to directly increase muscle protein synthesis or build muscle mass like anabolic compounds
mixed · TB-500 Peptide Benefits: What the Science Says (Swolverine, 2026) ↗
No completed Phase 2 or Phase 3 randomized controlled trial exists for TB-500 (or full-length thymosin beta-4) in human tendinopathy, muscle strain, or ligament injury — the use case most relevant to peptide buyers has the weakest direct human evidence
What experts say — both sides
Published 'Thymosin β4: a multi-functional regenerative peptide' (Expert Opinion on Biological Therapy, 2012), establishing thymosin beta-4 as a legitimate research target with multi-functional regenerative properties including cell migration and tissue remodeling. However, this work addresses full-length thymosin beta-4, not the TB-500 fragment.
Expert Opinion on Biological Therapy (2012); referenced in TB-500 research literature ↗
September 2024 Medical Evidence review acknowledges preclinical regenerative potential but emphasizes: 'The cumulative body of preclinical musculoskeletal work supports tissue-level effects relevant to wound healing, though no completed phase 2 or phase 3 RCT has tested systemic injectable thymosin beta-4 (or TB-500) for human tendinopathy, muscle strain, or ligament injury.'
Positions TB-500 as high-risk with limited safety data: 'TB-500 is not approved by the FDA for human use and is sold only as a research chemical. Long-term systemic safety data in humans remains limited, and the peptide is banned by WADA/USADA for all competitive athletes.'
Safety & legal status
**Regulatory Status:** TB-500 is NOT FDA-approved for any indication and has no recognized therapeutic use by any global regulatory authority. It is sold exclusively as a \"research chemical\" with \"research use only / not for human consumption\" labeling mandatory. **Research-Use Only Framing Required:** All marketing must explicitly state research-only status. Any marketing suggesting human therapeutic benefit converts the product to an unapproved drug in FDA eyes, regardless of labeling. Sellers cannot imply dosing protocols, recovery timelines, or human application. **Critical Human Safety Gap:** Zero completed Phase 2 or Phase 3 human clinical trials exist for TB-500 or systemic injectable thymosin beta-4 in musculoskeletal injury — the primary buyer use case has NO human efficacy or safety database. Preclinical data exists but does not predict human outcomes. **Doping Status:** TB-500 is banned by WADA (World Anti-Doping Agency) and USADA (U.S. Anti-Doping Agency) for all competitive athletes; it is prohibited at all times with no therapeutic use exemptions. **Important Distinction:** Most published research involves full-length thymosin beta-4 (43 amino acids), not the TB-500 fragment (5 amino acids / 17-23 fragment). Extrapolating full-length animal data to TB-500 is not scientifically valid. **Quality Control:** TB-500 suppliers must provide batch-specific third-party COAs (HPLC purity >98%, mass spectrometry, endotoxin/sterility) from independent labs (MZ Biolabs, Janoshik, Finnrick). Verify batch numbers match product vials; generic COAs indicate low credibility.
Research use only. Nothing here is medical or dosing advice.
TB-500 — FAQ
What is TB-500 vs. thymosin beta-4?
TB-500 is a 5-amino-acid synthetic fragment (amino acids 17-23) of the full 43-amino-acid thymosin beta-4 protein. Most published research involves full-length thymosin beta-4, not TB-500. TB-500 is sold as a research chemical; full-length thymosin beta-4 has limited clinical trial activity (e.g., Phase IIb cardiac study completed 2023).
Is there human clinical evidence that TB-500 works for muscle recovery?
No. Zero completed Phase 2 or Phase 3 human trials exist for TB-500 or systemic thymosin beta-4 in muscle strain or tendon injury. Preclinical animal studies show promise, but human clinical efficacy is completely unproven.
Is TB-500 approved by the FDA?
No. TB-500 is not FDA-approved and has no recognized medical use by any regulatory authority. It exists solely as a research chemical for laboratory use, not human consumption.
Can athletes use TB-500?
No. TB-500 is banned by WADA and USADA for all competitive athletes since 2022. It is classified as a non-approved substance with zero therapeutic use exemptions.
How does TB-500 compare to BPC-157?
Both are research peptides with limited human data. BPC-157 excels at localized tissue repair (tendons, ligaments, gut); TB-500 shows systemic cell migration and angiogenesis. Most clinicians stack both for complementary mechanisms, though neither has completed Phase 2/3 human trials for musculoskeletal injury.
What is the mechanism of TB-500?
TB-500 acts as an actin-binding protein that promotes cell migration, angiogenesis (new blood vessel formation), and inflammation reduction. It supports tissue remodeling and fibroblast activity in preclinical models, but its exact human mechanism remains under research.
See which vendors pass our audit for TB-500.
Why trust this comparison
- Every vendor is scored from real evidence on four public, weighted axes — before we know any margins.
- Purity claims are cross-checked against named third-party labs (MZ Biolabs, Finnrick, Janoshik). Claim-only purity is marked as such.
- The scoring code can't read which vendor pays us — the editorial-commerce firewall is enforced in software.
- We disclose the 20% / 10% Alpha Pro commission on every page, above the first link.
Vendors out-rank our own partner: Peptide Partners (9.0) and Protide Health (8.9) and Ascension Peptides (8.8) both score above Alpha Pro (8.6). We left it that way.